AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact

AntoXa Corporation granted Defence R&D Canada license for novel, plant-made anti-ricin antibody

April 16, 2018 By antoxa

GUELPH, Ont., Canada, April 16, 2018— AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide.

The licensing agreement follows work AntoXa and the J.C. Hall laboratory at the University of Guelph conducted with DRDC to develop and produce the plant-made antibody PhD9 as a medical countermeasure for ricin exposure, a program that has received more than $600,000 (CAD) from the Government of Canada since 2014.

“We anticipate market entry for the PhD9 anti-ricin antibody within two to three years, a timeline that is dependent on raising the necessary funds for scale up and other activities necessary to obtain regulatory approvals,” said Ashley Meyers, AntoXa Chief Technical Officer.

“This antibody will be produced in the vivoXPRESS® plant-based manufacturing system licensed from PlantForm Corporation, which uniquely addresses the critical need for cost-effective, large-scale production of antidotes for ricin and other potential terrorism threats.”

Ricin is a naturally occurring protein from the castor-bean plant, Ricinus communis. It is extremely toxic to humans when inhaled or injected and is listed as a Category B threat agent by the U.S. Centers for Disease Control and Prevention due to its ease of production, worldwide availability, relative stability and extreme lethality. There is currently no approved antidote against ricin poisoning. It acts very quickly and leaves a short window for administering therapeutic antibodies.

The PhD9 antibody drug candidate prevents ricin from penetrating cells. DRDC conducted in vitro and in vivo studies that found the plant-made version of the antibody showed therapeutic efficacy against ricin intoxication. The findings were presented at the Antibody Engineering and Therapeutics Conference in December 2015.

Next steps for the commercialization of PhD9 are transitioning to large-scale GMP manufacturing, product characterization, animal safety and efficacy studies, and a Phase 1 human clinical trial. Medical countermeasures do not require Phase 2 and Phase 3 human efficacy trials for ethical reasons, therefore the path to regulatory approval is shorter than for other pharmaceuticals.

About AntoXa Corporation (www.antoxacorp.com)

AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents, as well as outbreaks of naturally occurring infectious diseases.

A wholly-owned subsidiary of PlantForm Corporation, AntoXa holds an exclusive licence to the vivoXPRESS® biopharmaceutical manufacturing platform to produce countermeasures for ricin, sarin, soman and Ebola Sudan, as well as other defence-related therapeutics.

vivoXPRESS® technology uses genetically engineered tobacco plants to produce biopharmaceuticals in less than six weeks at a significantly lower cost of goods compared to industry standard fermentation systems.

– end –

For more information, please contact:

Don Stewart
President and CEO, AntoXa Corp.
don.stewart@antoxacorp.com
+1 416-452-7242

Stacey Curry Gunn
Director of Communications, AntoXa Corp.
stacey.curry.gunn@antoxacorp.com
+1 519-827-1131

Filed Under: News Releases, Products

Jim Rae

September 15, 2017 By antoxa

Jim Rae has more than 30 years of experience in the manufacturing, marketing, financial, human resource and R & D operations of pharmaceutical and biotechnology firms. He is experienced in raising funds and financing from public, private and government sectors.

Mr. Rae is President and founder of Remedis, a consultancy specializing in the restructuring and financing of health care businesses. Career highlights also include: Chairman of the Board of Directors of Bioniche Life Sciences Inc., President and CEO of Viron Therapeutics Inc., and President and CEO of Cangene; Chairman and CEO of Vaxis Therapeutics Inc.; Chairman and CEO of Resolution Pharmaceuticals; and CEO of Cytochroma Inc.

Mr. Rae is the Chairman of Queen’s Scientific Breakthrough Fund and holds directorships in a number of Canadian biotech companies.

Filed Under: Management Team

Don Stewart

September 15, 2017 By antoxa

Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. He is also the founder and President of Alba Biologics Group.

Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs; supervised animal efficacy and toxicology studies as well as clinical trial programs; and obtained more than $15 million in external grant and contract funding over a five-year period.

Dr. Stewart has a PhD in biochemistry from the University of London in the U.K. He has given numerous lectures at international symposia on research management, manufacturing strategies and biosimilar pharmaceuticals.

Filed Under: Management Team

J. Christopher Hall

September 15, 2017 By antoxa

Dr. Chris Hall is a world expert in the science of plant-based pharmaceutical production. He is a University Professor Emeritus in the School of Environmental Sciences at the University of Guelph and a former Tier 1 Canada Research Chair in Recombinant Antibody Technology (2002-2014).

Dr. Hall leads a dynamic team of PlantForm researchers who, with every new discovery, take another step towards establishing the company’s plant-based manufacturing platform as a superior system for biopharmaceutical production.

Dr. Hall first recognized the manufacturing and regulatory advantages of using tobacco plants to produce antibody drugs in the early 1990s. His technology overcomes a number of issues associated with animal-derived antibody production: it allows for higher yields, lowers costs and eliminates animal welfare concerns.

Dr. Hall’s research group also studies the large-scale production of antibodies in plants against food- and water-borne pathogens, biological weapons and environmental contaminants. His laboratory has published more than 150 papers in refereed journals.

Filed Under: Management Team

Ashley Meyers

September 15, 2017 By antoxa

Ashley Meyers has over 10 years of experience in biopharmaceutical development that includes research and development of recombinant proteins and production of these products for pre-clinical studies. Ms. Meyers has been leading medical countermeasure research and development programs since 2012 and has collectively secured over $2.2 million towards advancing these programs. She has over five years of experience as a project manager for government-funded contracts for PlantForm Corporation.

Ms. Meyers completed a MSc degree in protein engineering in plants from the University of Guelph under the supervision of Dr. J. Christopher Hall, PlantForm’s co-founder and Chief Scientific Officer.

Filed Under: Management Team

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2022 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates